These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 31121839)

  • 1. Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis.
    Bazwinsky-Wutschke I; Zipprich A; Dehghani F
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31121839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoids signaling: Molecular mechanisms of liver regulation and diseases.
    Wang M; Meng N; Chang Y; Tang W
    Front Biosci (Landmark Ed); 2016 Jun; 21(7):1488-501. PubMed ID: 27100518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.
    Mallat A; Lotersztajn S
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G9-G12. PubMed ID: 17975129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal high-fat diet consumption induces sex-dependent alterations of the endocannabinoid system and redox homeostasis in liver of adult rat offspring.
    Miranda RA; De Almeida MM; Rocha CPDD; de Brito Fassarella L; De Souza LL; Souza AFP; Andrade CBV; Fortunato RS; Pazos-Moura CC; Trevenzoli IH
    Sci Rep; 2018 Oct; 8(1):14751. PubMed ID: 30282988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocannabinoids and their role in fatty liver disease.
    Mallat A; Lotersztajn S
    Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid signaling and liver therapeutics.
    Mallat A; Teixeira-Clerc F; Lotersztajn S
    J Hepatol; 2013 Oct; 59(4):891-6. PubMed ID: 23567085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
    Lin HC; Yang YY; Tsai TH; Huang CM; Huang YT; Lee FY; Liu TT; Lee SD
    J Hepatol; 2011 Jun; 54(6):1145-53. PubMed ID: 21145843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.
    Baldassarre M; Giannone FA; Napoli L; Tovoli A; Ricci CS; Tufoni M; Caraceni P
    Liver Int; 2013 Oct; 33(9):1298-308. PubMed ID: 23890208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocannabinoids as novel mediators of liver diseases.
    Mallat A; Lotersztajn S
    J Endocrinol Invest; 2006; 29(3 Suppl):58-65. PubMed ID: 16751709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perinatal maternal high-fat diet induces early obesity and sex-specific alterations of the endocannabinoid system in white and brown adipose tissue of weanling rat offspring.
    Almeida MM; Dias-Rocha CP; Souza AS; Muros MF; Mendonca LS; Pazos-Moura CC; Trevenzoli IH
    Br J Nutr; 2017 Nov; 118(10):788-803. PubMed ID: 29110748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis.
    Siegmund SV; Schwabe RF
    Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G357-62. PubMed ID: 18006606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The endocannabinoid system and its role in regulation of metabolism in peripheral tissues].
    Rumińska A; Dobrzyń A
    Postepy Biochem; 2012; 58(2):127-34. PubMed ID: 23214136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic expression of cannabinoid receptors CB1 and CB2 correlate with fibrogenesis in patients with chronic hepatitis B.
    Dai E; Zhang L; Ye L; Wan S; Feng L; Qi Q; Yao F; Li Z
    Int J Infect Dis; 2017 Jun; 59():124-130. PubMed ID: 28315398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrogenic role of the cannabinoid receptor CB2 in the liver.
    Julien B; Grenard P; Teixeira-Clerc F; Van Nhieu JT; Li L; Karsak M; Zimmer A; Mallat A; Lotersztajn S
    Gastroenterology; 2005 Mar; 128(3):742-55. PubMed ID: 15765409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cannabinoids in chronic liver diseases.
    Parfieniuk A; Flisiak R
    World J Gastroenterol; 2008 Oct; 14(40):6109-14. PubMed ID: 18985799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocannabinoids in liver disease.
    Tam J; Liu J; Mukhopadhyay B; Cinar R; Godlewski G; Kunos G
    Hepatology; 2011 Jan; 53(1):346-55. PubMed ID: 21254182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocannabinoid System Contributes to Liver Injury and Inflammation by Activation of Bone Marrow-Derived Monocytes/Macrophages in a CB1-Dependent Manner.
    Mai P; Yang L; Tian L; Wang L; Jia S; Zhang Y; Liu X; Yang L; Li L
    J Immunol; 2015 Oct; 195(7):3390-401. PubMed ID: 26320250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocannabinoid Signalling in Atherosclerosis and Related Metabolic Complications.
    Guillamat-Prats R; Rami M; Herzig S; Steffens S
    Thromb Haemost; 2019 Apr; 119(4):567-575. PubMed ID: 30769363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis.
    Melgar-Lesmes P; Perramon M; Jiménez W
    Cells; 2019 Oct; 8(11):. PubMed ID: 31653030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.
    Pascual AC; Gaveglio VL; Giusto NM; Pasquaré SJ
    Exp Gerontol; 2014 Jul; 55():134-42. PubMed ID: 24768821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.